In making the two previous determinations about THC, why did FDA conclude that THC is an active ingredient in a drug product that has been approved under section 505 of the FD&C Act? In making the two previous determinations about CBD, why did FDA determine that substantial clinical investigations have been authorized for and/or instituted, and that the existence of such investigations has been made public?
According to PeaceHealth, a website dedicated to providing information on an array of different supplements and medications, hemp oil can cause minor side effects in the digestive system. For example, the website suggests that hemp and hemp oil can soften the stools, often leading to diarrhea or abdominal cramping. Many times, excessive diarrhea can lead to increased weight loss or malabsorption. While further research is needed to substantiate these side effect claims, it is recommended that for individuals with a history of digestive disorders or irregular bowel movements to not take hemp oil supplements.
CBD has also been shown to have neuroprotective properties in cell cultures as well as in animal models of several neurodegenerative diseases, including Alzheimer’s,xii,xiii,xiv stroke,xv glutamate toxicity,xvi multiple sclerosis (MS),xvii Parkinson’s disease,xviii and neurodegeneration caused by alcohol abuse.xix Nabiximols (trade name Sativex), which contains THC and CBD in roughly equal proportions, has been approved throughout most of Europe and in a number of other countries for the treatment of spasticity associated with MS. It has not been approved in the United States, but clinical trials are ongoing, and two recent studies reported that nabiximols reduced the severity of spasticity in MS patients.xx,xxi There have been limited clinical trials to assess the potential efficacy of CBD for the other indications highlighted; however, a recent small double-blind trial in patients with Parkinson’s disease found the CBD improved quality-of-life scores.xxii
Success stories like Oliver’s are everywhere, but there’s not a lot of data to back up those results. That’s because CBD comes from cannabis and, like nearly all other parts of the plant, is categorized by the Drug Enforcement Agency (DEA) as a Schedule 1 drug—the most restrictive classification. (Others on that list: heroin, Ecstasy, and peyote.) This classification, which cannabis advocates have tried for years to change, keeps cannabis-derived products, including CBD, from being properly studied in the U.S.
A 2013 study conducted at the University of Haifa in Israel found that cannabinoid treatment after a traumatic experience may regulate the emotional response to the trauma and prevent stress-induced impairment. Cannabinoid treatment minimized the stress receptors in the basolateral amygdala (the nuclei that receives that majority of sensory information) and hippocampus (the part of the brain that is thought to be the center of emotion). (4)
This content is strictly the opinion of Dr. Josh Axe and is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of medical advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. Neither Dr. Axe nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information in this educational content. All viewers of this content, especially those taking prescription or over-the-counter medications, should consult their physicians before beginning any nutrition, supplement or lifestyle program.
As for phytocannabinoid-rich hemp oil, due to the presence of the hemp plant’s cannabinoids there are many additional uses and benefits with practically zero side effects. The most common use of this type of hemp oil is for chronic pain management, but many people also use it to treat some symptoms of cancer, among other diseases and conditions. Even the Food and Drug Administration recently approved a new CBD-based prescription medication.
Serotonin: Most people associate serotonin with happiness. However, the role of this neurotransmitter is very complex, and its effects depend on where it is and what it binds to. (Contrary to popular belief, more serotonin is not necessarily better — dysfunction can stem from low or high levels of serotonin, as well as from malfunctions with their receptors.) Serotonin has at least 14 different receptors, but CBD specifically binds to 5-HT1A which is thought to have the strongest role in anxiety disorders. The anti-anxiety drug buspirone also binds to this particular receptor, which explains the anti-anxiety effects of CBD on rats exposed to stressful situations.
I have a slightly bulging disc in my back that has been causing neuropathy in my left leg for years. I’ve had several rounds of trigger point injections; see a physical therapist regularly, and lately a chiropractor as well. The next step for me would be to try an epidural pain block. Several of my other doctors are big proponents of the “inflammation as a cause of disease” theory and have really encouraged me to do things to reduce inflammation. Omega-3 fatty acids in particular help with this (as most Americans consume a poor ratio of omega-6 to omega-3 which can increase inflammation.) Hemp products contain phytocannabinoids, a substance that can help decrease pain and inflammation. This is full spectrum hemp oil derived from hemp seeds—meaning it contains all of the phytocannabinoids and not just one in particular. This is NOT CBD (cannabidiol) oil, although based on my research it likely contains low levels of CBD. CBD is the substance produced from hemp flowers (a plant with little to no THC—the substance that causes a high) (or marijuana flowers—a plant in the same family with significant THC) that is widely known to have medicinal purposes in pain relief, stopping seizures, etc.
CBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as "nabiximols") as the brand name product Sativex. It is approved for use as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS). Sativex was also given a conditional Notice of Compliance (NOC/c) for use as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis and as adjunctive analgesic treatment for moderate to severe pain in adult patients with advanced cancer .